Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bee venom + capsaicin (Rubeeven) is a topical analgesic cream developed by the New Zealand-based company HoneyLab. The formulation combines the desensitizing effects of capsaicin with the anti-inflammatory properties of bee venom (apitoxin). Capsaicin acts as a potent agonist of the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor; chronic application leads to the depletion of Substance P and the desensitization of nociceptive nerve fibers. Bee venom contains various bioactive peptides, most notably melittin, which has been studied for its ability to modulate inflammatory pathways and provide relief in musculoskeletal conditions such as arthritis and muscle strains. The product is marketed as a natural alternative for the management of joint and muscle pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bee venom + capsaicin.